Caffeine citrate - Chiesi Farmaceutici

Drug Profile

Caffeine citrate - Chiesi Farmaceutici

Alternative Names: Nymusa; Peyona

Latest Information Update: 05 Mar 2015

Price : $50

At a glance

  • Originator Chiesi Farmaceutici
  • Class Respiratory stimulants; Small molecules; Xanthines
  • Mechanism of Action Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Apnoea
  • New Molecular Entity No

Highest Development Phases

  • Marketed Apnoea

Most Recent Events

  • 23 Apr 2009 Committee for Medicinal Products for Human Use recommends approval of caffeine citrate for Apnoea (in neonates) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top